Scienion offers complete solutions for parallel bioanalytics and high throughput production/screening of microarrays in genomics and proteomics. The company specializes in ultra low volume liquid handling, particularly for precious and sensitive compounds of biological or chemical origin. On August 20th, 2020, Scienion was acquired by Cellink.83M.
Scienion has filed 13 patents.
Cell biology, Colloidal chemistry, Biotechnology, Quantum mechanics, Microscopy
Cell biology, Colloidal chemistry, Biotechnology, Quantum mechanics, Microscopy
Latest Scienion News
Apr 4, 2023
insights from industryHolger EickhoffFounder and CEOScienion In this interview, we speak to Holger Eickhoff, CEO and Founder of Scienion, about their latest technology, The Nucleus Automation Ecosystem, and how it will bring new flexibility to the manufacturing market in life sciences. Please can you introduce yourself and tell us about your role at Scienion? My name is Holger Eickhoff, and I am the Founder and CEO of Scienion. I have had the same job description for the last 22 years. Scienion is a global leader in precision dispensing, using your products to accelerate the life sciences by providing accessible solutions combining both biology and technology. Can you tell us more about Scienion and your core aims and values? Scienion is essentially two words merged into one; science and vision. This is how we came up with the company name. Our customers are our main priority, as we dispense and assay development solutions to allow for precision medicine, a major personal health development. Can you tell us what the term’ precision dispensing’ means and what sectors it benefits in the life sciences? Precision dispensing refers to reproducibility, ensuring precision in the screening and medical testing fields. The more precise we can dispense reagents , the more precise the diagnosis. From this, we can sense, for example, if people have an autoimmune disorder or an allergy with high specificity. Image Credit: maxuser/Shutterstock.com Currently, you have a variety of services and products available for customers that encompasses automation, multiplex analysis, and miniaturization. Can you tell us more about some of your core products and how they are able to benefit all aspects of life sciences research from its initial phases all the way through to high throughput production? We accompany our customers from the early stages of product development through to manufacturing. Essentially, if the product makes it to market, we provide technologies that facilitate the production of as many products as required. Throughout the pandemic, we carried out various tests, and the lateral flow test strips and PCR tests that are so familiar today are all based on our technology. We can either sell our customer’s equipment to aid in the production of millions of tests or contract manufacturers that have the capacity to test in-house. We are almost a one-stop shop for life science solutions. Moreover, we are attentive to our customer’s needs; we do not just sell the equipment. For instance, if our customer wants us to conduct tests for them, we can absolutely accommodate this and transfer the results to them later down the line. In other words, we provide solutions to our customer’s problems, regardless of what scientific challenge needs to be addressed. In a rapidly advancing market, we find this is the best strategy. Scienion has recently launched its latest product, The Nucleus Automation Ecosystem, a fully integrated platform bringing new flexibility to the manufacturing market. Can you tell us more about this platform and how it works? The Nucleus Automation Ecosystem is a fully integrated platform that offers advancements in modularity, scalability, and flexibility. If we were to compare the Nucleus to an iPhone, the Nucleus Automation Ecosystem would be similar to an app. We can also offer a MacBook Pro if the user wants to upscale this. The system has base modules where you can carry out a process, validate it, and then scale it to any scale. It fits our current philosophy very well. We are currently working with new industry-leading components and have received very good feedback on the concept thus far. Scienion - SLAS 2023 With various new automated equipment becoming available in the life sciences, what makes your product unique? Being able to validate a complete process in one module and then scale to any scale based on the customer’s needs makes our offering so unique, and this goes beyond any of the dispensed solutions we currently provide. It is a combination of dispensing substrate handling, gluing, welding, etc., as opposed to getting a complete diagnostic test kit or a pharmaceutical device manufactured and then having to scale it further down the line. The Nucleus Platform also reduces the carbon footprint of processes due to them being housed in the same enclosure. Why was it important to design a product that was not only precise but environmentally friendly too? Offering a ‘clean,’ environmentally friendly product is crucial as we want to be able to market this product worldwide. At present, it is hard to find a clean room that can produce accurate diagnostic tests in every part of the world. Related Stories Additionally, the process steps are housed within the same enclosure, reducing the system’s overall footprint. It is also fully autonomous with its own clean room, including humidification, air conditioning, etc. This allows for significant cost savings as the user does not require an external large clean room with additional utility beds. This is a great advantage for our customers. The reduced footprint is also a massive advantage for researchers as worktop space is in high demand. Researchers are currently conducting groundbreaking research within a tiny space, and we hope this modular system will be a good solution to this, allowing R&D to be carried out all in one place. Then, if it needs to be scaled up, this can be done in a hall rather than in a clean room, which is much more environmentally friendly. How will The Nucleus continue to support your current customers as well as provide new opportunities in fields such as medical devices? Our existing customer base loves the new platform, as it means that we can keep adding processes that are not currently part of our offering, and we are doing this with industry-standard automation systems. For the medical device industry, this offering is more of a finished product than just a segment of it, and this is very much appreciated within the field. Image Credit: sfam_photo/Shutterstock.com You are currently showcasing the first prototype of the platform at SLAS 2023, allowing people to see and watch live demonstrations. How important is this for your customers, and what value do international exhibitions like SLAS have when launching new products? Being able to showcase the platform prototype at exhibitions such as SLAS means materializing a concept we have spoken about. This helps to build a sense of trust throughout the industry, as people can come over, see the product, feel it, and, most importantly, test it. This is also a great opportunity for individuals to learn more about our new offering and ask any questions they may have, speaking first-hand to the experts who know the product inside and out. Typically, strong client relationships take years to develop; there is no shortcut. Working with the right partner is critical; speaking to company representatives at exhibitions like SLAS is a key starting point in this journey. Despite the difficulty of transporting it from Europe, we are very proud to be able to showcase our prototype at SLAS. At Scienion, you are also strongly committed to R&D, taking part in both internal research efforts as well as participating in various national and international research projects. Why is this, and how important is collaboration to these projects? Scienion is a very collaborative company, and it is so important that we are able to collaborate with our customers. Within R&D, we sponsor and collaborate with world-leading research organizations. We consider ourselves a part of cutting-edge science. We do not want to provide only a tool but also the knowledge behind it. Collaboration is key to Scienion’s future success, as what we see in the lab today will potentially become available on the market in the next six to eight years. Image Credit: Pressmaster/Shutterstock.com Are you hopeful that with continued technological advancements, we will continue to see improved diagnostic and bioanalysis test platforms? What would this mean for patients, consumers, and public health worldwide? When people go to the doctors, they face the ‘Stone Age’ technology that is still in use. This is what motivates us to carry out the work that we do at Scienion. For instance, imagine a technology that is able to provide single-cell resolution in oncology, with the potential to ensure a patient with a tumor leaves the hospital with zero oncologic cells. We will keep working hard until these concepts materialize and this technology is implemented. It would also be revolutionary to democratize results, making them more understandable for an everyday individual who lacks specialized medical knowledge. This will be a big collaborative effort between doctors and clinics, but this is something that we are in the middle of working on. What is next for Scienion? Are you involved in any exciting upcoming projects? The future is unclear in terms of upcoming projects. Ideally, we want to follow the trends. One trend that we are seeing is that our developments and products intended for life science and diagnostics will become lifestyle products, such as sensors in watches and wristbands. We see business moving in this direction and entering the mainstream. We have entertained such applications over the last five to six years, and we see this becoming a mega-trend in the near future. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
Scienion Frequently Asked Questions (FAQ)
When was Scienion founded?
Scienion was founded in 2001.
Where is Scienion's headquarters?
Scienion's headquarters is located at Volmerstrasse 7b, Berlin.
What is Scienion's latest funding round?
Scienion's latest funding round is Acquired.
Who are the investors of Scienion?
Investors of Scienion include BICO, NRW.Bank, S-Venture Capital Dortmund, ERP-Startfonds, IBB Beteiligungsgesellschaft and 6 more.
Who are Scienion's competitors?
Competitors of Scienion include Pepscan, WaferGen Bio-systems, HTG Molecular Diagnostics, Expression Analysis, BioSystem Development and 13 more.
Compare Scienion to Competitors
Neuromedical Systems, Inc. a development stage company develops, manufactures and markets systems for computer assisted screening of pap smears and other cytological specimans. The company's product papnet testing system is used in laboratories in detection of abnormal cells on pap smears. Papnet is also used in detection of bladder and lung cancer. During the year, the company acquired New System International, Ltd. The company has international operations in Europe, Israel, Asia and Australia.
Employing recent advances in sequencing, ASPE bead array, microarray technology, Q'Array is poised to provide a range of DNA testing, including genetic, chromosomal, biochemical, pharmacogenomics, paternity, and forensic identity testing.
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.
Oxford Molecular aims to provide computational chemistry and molecular graphics to European and U.S. markets.